INTERCEPT-AD试验后参与者对1期试验体验的定性访谈研究
结果显示参与者因个人获益和利他动机参加,但与工作人员互动积极的同时,旅行、时间投入和研究程序带来显著负担,认知测试比侵入性操作更具挑战性。参与者希望获得更清晰的沟通和更多研究相关信息。
要点
- 参与者参与动机包括预期个人获益和利他目标,入组决策有独立和家庭参与两种模式。
- 试验相关负担主要来自旅行、时间投入和研究程序,认知测试比侵入性操作更常被描述为挑战。
- 参与者渴望更清晰的沟通和更多研究相关信息(如检测结果和治疗分配)。
核心结论
- 研究提示可通过解决试验相关负担和后勤方面来改善阿尔茨海默病试验体验。
- 探索性性别分析提供了额外见解,但需进一步结合种族/族裔和研究伙伴特征 examined。
研究设计与样本
- 在INTERCEPT-AD 1期试验完成后,对参与者/研究伙伴二元组进行半结构化定性访谈。
- 采用应用定性主题分析原则分析,并探索性分析性别差异。
主要发现
- 参与者和研究伙伴描述了不同的试验知晓和入组决策路径,包括独立和家庭参与决策。
- 参与动机反映预期个人获益和利他目标。
- 与研究工作人员互动被视为积极,但二元组报告了旅行、时间投入和研究程序相关的显著负担。
- 认知测试比侵入性操作更频繁地被描述为具有挑战性。
- 一个反复出现的主题是希望更清晰的沟通和更多研究相关信息,包括检测结果和治疗分配。
临床怎么用
- 在阿尔茨海默病试验设计中应关注减轻旅行、时间投入和研究程序等负担。
- 应加强与研究参与者的沟通,提供更清晰的研究相关信息(如检测结果和治疗分配)。
局限性
- 探索性性别分析结果需进一步研究,并结合种族/族裔和研究伙伴特征加以检验。
- 访谈仅纳入完成试验的参与者亚组,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recruitment and retention remain persistent challenges in Alzheimer's disease (AD) clinical trials, particularly as studies increasingly focus on earlier disease stages and require longer participation and more invasive procedures. Understanding how trial enrollment and participation are experienced is critical to improving acceptability and sustaining engagement. Qualitative interviews conducted alongside clinical trials offer an opportunity to capture participant and study partner perspectives on the trial experience. In INTERCEPT-AD, a phase 1 trial evaluating safety and tolerability of the Aβ oligomer-selective monoclonal antibody sabirnetug (ACU193) among participants with mild cognitive impairment or mild dementia due to Alzheimer's disease (AD), semi-structured qualitative interviews concerning trial experience were conducted with a subset of participants and their study partners. METHODS: Participant/study partner dyads completed qualitative interviews following the final study visit. A semi-structured interview guide elicited descriptions regarding motivations for participating, enrollment decision-making, and positive and negative aspects of participation. Principles of applied qualitative thematic analysis guided the qualitative analyses. Exploratory analyses examined how factors differ by participant gender. RESULTS: Twenty-eight participants (64.2% female) and their study partners were interviewed, representing 43% of the trial population (n = 65; 53.8% female). Participants and study partner dyads described varied pathways to trial awareness and enrollment decision-making, including both independent and family-involved decisions. Motivations for participation reflected anticipated personal benefit as well as altruistic goals. While interactions with study staff were viewed positively, dyads reported meaningful burdens related to travel, time commitment, and study procedures, with cognitive testing more frequently described as challenging than invasive procedures. A recurring theme was the desire for clearer communication and greater access to study-related information, including test results and treatment assignment. Exploratory analyses suggested that perceived burden and enrollment decision-making may differ by participant gender. CONCLUSIONS: Study findings suggest opportunities to enhance the AD trial experience by addressing trial-related burdens and logistical aspects of participation. Exploratory gender analyses yielded additional insight into the patient trial experience but should be further examined along with race/ethnicity and study partner characteristics to enhance clinical study design and execution.
引用
- Merikle E, Presnall C, Feaster T, et al. Elucidating the phase 1 trial experience among study participants following completion of the INTERCEPT-AD study of sabirnetug (ACU193) for early Alzheimer's disease: a qualitative interview study. Trials. 2026. PMID: 41872889. doi:10.1186/s13063-026-09656-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。